Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (250)	12/9/1997 9:48:00 AM
From: 5,17,37,5,101,...	Read Replies (2) \| Respond to of 756

That post sounds a bit fishy. I don't trust especially the yahoo thread and so will not read it. On the other hand, the previous CEO was jettisoned for reasons not disclosed, but possibly because of his failure to sell nonperforming assets.* I doubt it. The present downtrend from $12.50 to $7.00 occurred shortly after the FDA panel approval of Paxene. IMHO, the market was pricing IVX based upon expectations of Paxene approval, which seem quite low. *Ivax said Strauss' decision to leave was personal, but said Strauss cited "differing management styles and vision for the company." WSJ 7/97 Note: I wish Frost would share his vision with shareholders! Rational was a screaming buy at 7 obviously. Here, I am thinking acquisition by another company. The volume looks good -- famous last words. I have a very small position: 200 shares, in hopes that it will decline to ~$9.00 to $10.00 area where I will seriously average down. This is one I missed because the mail did not deliver insider letter. Jackson